Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04451330 · ClinicalTrials.gov registry record · Phase 4
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
A Phase 4 study of Acne Vulgaris, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT04451330 is a Phase 4 study of Acne Vulgaris that has completed, run by Galderma R&D. The registered enrollment target is 202 participants, below the 272-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04451330, a Phase 4 study of Acne Vulgaris, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
Conditions Studied
Interventions
- DRUG Trifarotene cream
- DRUG Doxycycline hyclate
- DRUG Trifarotene Vehicle
- DRUG Doxycycline Placebo
Study Locations (20)
Arkansas
- Galderma Investigational Site - Fort Smith
- Galderma Investigational Site - Hot Springs
- Galderma Investigational Site - Rogers
Florida
- Galderma Investigational Site - Aventura
- Galderma Investigational Site - Boca Raton
- Galderma Investigational Site - Miramar
Indiana
- Galderma Investigational Site - Evansville
- Galderma Investigational Site - New Albany
California
- Galderma Investigational Site - Newport Beach
Georgia
- Galderma Investigational Site - Newnan
Maryland
- Galderma Investigational Site - Rockville
Michigan
- Galderma Investigational Site - Warren
Minnesota
- Galderma Investigational Site - New Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04451330
The ClinicalTrials.gov registry entry for NCT04451330 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (26% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 4 interventions - of which Trifarotene cream is the first listed.
NCT04451330 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Arkansas, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT04451330 about?
NCT04451330 is a clinical study titled "A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)". The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
What is the current status of trial NCT04451330?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 202 participants. The study started on 2020-07-29. Estimated completion is 2021-04-26.
What conditions does trial NCT04451330 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT04451330?
The interventions under investigation include: Trifarotene cream (DRUG), Doxycycline hyclate (DRUG), Trifarotene Vehicle (DRUG), Doxycycline Placebo (DRUG).
Who is sponsoring clinical trial NCT04451330?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04451330 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
ACTIVE NOT RECRUITING · Phase 4
-
Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 4
-
AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
COMPLETED · Phase 4
-
Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%
COMPLETED · Phase 4
-
Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications
COMPLETED · Phase 4
-
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.